Vir Biotechnology (VIR) Non-Current Deffered Revenue (2018 - 2025)

Vir Biotechnology has reported Non-Current Deffered Revenue for 8 years, with the latest figure at $9.4 million in Q3 2025.

• Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $9.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $9.4 million (changed N/A YoY) and the FY2023 annual result came in at $1.5 million, down 97.13% from the prior year.
• Non-Current Deffered Revenue advanced to $9.4 million in Q3 2025 per VIR's latest filing, from $1.5 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $55.5 million in Q2 2021 and troughed at $1.5 million in Q4 2023.
• A 5-year average of $25.5 million and a median of $7.6 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2021 and 2023: Non-Current Deffered Revenue jumped 1354.68% in 2021, then slumped 97.13% in 2023.
• Over 5 years, Non-Current Deffered Revenue stood at $3.8 million in 2021, then soared by 1294.68% to $53.2 million in 2022, then plunged by 97.13% to $1.5 million in 2023, then changed by 0.0% to $1.5 million in 2024, then soared by 518.15% to $9.4 million in 2025.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $9.4 million, $1.5 million, and $1.5 million for Q3 2025, Q1 2024, and Q4 2023 respectively.